Allvivo Vascular

Allvivo Vascular is a private, pre-revenue medical device company developing a novel antimicrobial technology platform centered on engineered peptides (ASP-1, ASP-2) and biocompatible formulations. The platform is designed to coat medical devices and treat wounds, offering broad-spectrum protection, biofilm eradication, and activity against multidrug-resistant bacteria with high biocompatibility. The company operates through collaborations with licensees and marketing partners, positioning its technology as a potential alternative to traditional antimicrobials like silver. Founded in 2003, Allvivo appears to be in a late-stage development or partnership-driven commercialization phase for its platform technologies.

Proprietary platform combining engineered antimicrobial peptides (ASP-1, ASP-2) with biocompatible formulation technology to create durable coatings for medical devices and biodegradable formats for wound treatment. The peptides act via membrane disruption to kill bacteria, including drug-resistant strains and biofilms, with high specificity for pathogens over host cells.

Allvivo competes with established antimicrobial coatings using silver, antibiotics, or antiseptics from major device companies. It also faces competition from other novel technology developers working on peptide coatings, nitric oxide release, and surface modification strategies. Differentiation hinges on demonstrating superior efficacy against biofilms and improved biocompatibility.